"Can we learn anything from the most clicked on posts? Possibly! BG12 is clearly of interest in particular its safety; I note readers were particularly interested in the cases of PML on fumaderm. Trials are of interest; I am glad our INSPIRE trial is top of the pops - we are about to screen our first MSer for this trial. CCSVI still attracts attention but is clearly fading in interest. And what more can I say about Pharma behaving badly? Hopefully they will start behaving well; we need them to."